Biohaven (BHVN) shares were up over 4% in recent trading on Wednesday after the company said its two drug candidates are near market and it is doing phase three testing for four other indications.

BHV-4157 for the treatment of spinocerebellar ataxia and BHV-2000 for spinal muscular atrophy are closer to the market stage, according to the company.

The company is evaluating BHV-4157 as a treatment for patients with obsessive-compulsive disorder in a phase three study.

Other late-stage candidates include BHV-7000 for focal and generalized epilepsies and BHV-8000 for Parkinson's disease, Biohaven said.

Price: 16.29, Change: +0.50, Percent Change: +3.17